Inside Drug Pricing - 12/02/2019

Sickle Cell Drug Oxbryta To Cost Majority Of Payers $8,000 A Month

By Beth Wang / November 27, 2019 at 11:52 AM
Global Blood Therapeutics said it is working with public and commercial payers to get broad coverage for its newly approved sickle cell drug Oxbryta (voxelotor) by the end of 2020. The drug has a list price, or wholesale acquisition cost, of more than $10,000 a month, and the company estimates it will cost the majority of payers about $8,000 per month, with more than half of patients expected to go through Medicaid or other federal programs. Oxbryta, a once-daily oral...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.